benzinga60d ago
Expanding clinical use, improved efficacy, and wider recognition of obesity as a chronic disease underpin sustained "double-digit" market growthLondon, UK – 6 February 2026 –The global anti-obesity drugs market is estimated at US$22.52 billion in 2026 and is projected to grow at a CAGR of 24.2% over the forecast period 2026-2036, reaching US$195.99 billion by 2036. Growth is driven by rising global obesity rates, improved clinical efficacy of newer therapies, and broader recognition of obesity as a chronic disease requiring long-term treatment.Key Market DriversRising global prevalence of obesity and related comorbiditiesStrong clinical outcomes from GLP-1 and multi-agonist therapiesIncreasing physician and patient awareness of pharmacological optionsOngoing innovation in drug formulation and delivery technologiesFull story available on Benzinga.com